Baclofen/diazepam

PreclinicalSmall molecule

DDr. John A. Thiel Medical Professional Corporation

Baclofen/diazepam is one of 19 small molecule programs targeting Myalgia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyalgiaActive, not recruiting

MyalgiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Myalgia

#DrugCompanyPhaseTrials

Olumiant

Bayer Aspirin

Aleve

Alnylam Pharmaceuticals

Voltaren

Advil

1 6

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—7

Esmeron

FFresenius Kabi Oncology Ltd.

Approved

—8

Ansaid

PPharmacia and Upjohn

Approved

—9

Oruvail

WWyeth-Lederle Vaccines

Approved

—10

Indocin

LLife Extension Foundation Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myalgia1 trial

Baclofen/Diazepam Supps for Treatment of Pelvic Floor Myalgia

Unknown status·—·N/A·NCT03427216·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Baclofen/diazepam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Baclofen/diazepam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Baclofen/diazepam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. John A. Thiel Medical Professional Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDr. John A. Thiel Medical Professional Corporation

Baclofen/diazepam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myalgia1 trial

References

Drug Info

Quick Facts

Related News